p.4 抽出テキスト

8.4. Wolff–Parkinson–White syndrome .......................................... 4090 8.5. Prevention of sudden cardiac death in the elderly ............. 4090 9. Key messages ............................................................................................... 4090 9.1. General aspects .................................................................................. 4090 9.2. Structural heart disease .................................................................. 4090 9.3. Primary electrical disease ............................................................... 4091 10. Gaps in evidence ...................................................................................... 4091 10.1. General aspects ............................................................................... 4091 10.2. Structural heart disease—general ........................................... 4091 10.3. Idiopathic premature ventricular complexes/ventricular tachycardia .................................................................................................... 4091 10.4. Coronary artery disease .............................................................. 4091 10.5. Cardiomyopathies .......................................................................... 4091 10.6. Valvular heart disease ................................................................... 4091 10.7. Congenital heart disease .............................................................. 4091 10.8. Primary electrical disease ............................................................ 4091 11. ‘What to do’ and ‘what not to do’ messages from the Guidelines ........................................................................................................... 4092 12. Quality indicators .................................................................................... 4099 13. Supplementary data ................................................................................ 4099 14. Data availability statement ................................................................... 4099 15. Author information ................................................................................ 4099 16. Appendix ..................................................................................................... 4100 17. References .................................................................................................. 4101

Tables of Recommendations

Recommendation Table 1 — Recommendations for public basic life support and access to automated external defibrillators ............................................................................................ 4014 Recommendation Table 2 — Recommendations for genetic testing ................................................................................................................... 4018 Recommendation Table 3 — Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia .......................................................................................................... 4018 Recommendation Table 4 — Recommendations for evaluation of patients presenting with a first episode of sustained monomorphic ventricular tachycardia ................................................... 4020 Recommendation Table 5 — Recommendations for evaluation of sudden cardiac arrest survivors ................................................................ 4022 Recommendation Table 6 — Recommendations for evaluation of sudden death victims ..................................................................................... 4023 Recommendation Table 7 — Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents ........ 4027 Recommendation Table 8 — Recommendations for treatment of reversible conditions ...................................................................................... 4029 Recommendation Table 9 — Recommendations for the acute management of sustained ventricular tachycardia and electrical storm .................................................................................................................... 4033 Recommendation Table 10 — Recommendations for treatment with heart failure medication ..................................................................... 4034 Recommendation Table 11 — Recommendations for implantable cardioverter defibrillator implantation (general aspects) .............. 4040 Recommendation Table 12 — Recommendations for secondary prevention of sudden cardiac death ....................................................... 4040 Recommendation Table 13 — Recommendations for subcutaneous implantable cardioverter defibrillator ....................... 4040 Recommendation Table 14 — Recommendations for adding cardiac resynchronization therapy to implantable cardioverter defibrillator ........................................................................................................ 4040 Recommendation Table 15 — Recommendations for wearable cardioverter defibrillator .............................................................................. 4040 Recommendation Table 16 — Recommendations for optimization of device programming ..................................................... 4041 Recommendation Table 17 — Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter defibrillator therapy ............................................................ 4042 Recommendation Table 18 — Recommendations for psychosocial management after implantable cardioverter defibrillator implantation ............................................................................. 4042 Recommendation Table 19 — Recommendations for implantable cardioverter defibrillator implantation in left ventricular assist device recipients .............................................................................................. 4042 Recommendation Table 20 — Recommendations for prevention of implantable cardioverter defibrillator complications ................. 4043 Recommendation Table 21 — Recommendations for end-of-life issues in implantable cardioverter defibrillator carriers ................. 4043 Recommendation Table 22 — Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm .......................................................................................................... 4046 Recommendation Table 23 — Recommendations for risk stratification and treatment of ventricular arrhythmias early after myocardial infarction ..................................................................................... 4046 Recommendation Table 24 — Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmias in chronic coronary artery disease ......... 4047 Recommendation Table 25 — Recommendations for sudden cardiac death prevention in patients with coronary anomalies ....... 4050 Recommendation Table 26 — Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia .......................................................... 4052 Recommendation Table 27 — Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy ............................................................................................................. 4053 Recommendation Table 28 — Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/ hypokinetic non-dilated cardiomyopathy ...................................... 4057 Recommendation Table 29 — Recommendations for diagnostic, risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy ........................................................................ 4060 Recommendation Table 30 — Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmias in hypertropic cardiomyopathy ............... 4062 Recommendation Table 31 — Recommendations for implantable cardioverter defibrillator implantation in left ventricular non-compaction .............................................................................................. 4063 Recommendation Table 32 — Recommendations for implantable cardioverter defibrillator implantation in patients with cardiac amyloidosis ......................................................................................................... 4063 Recommendation Table 33 — Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmias in neuromuscular diseases ......................... 4065 Downloaded from academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 07 October 2026